{"slug":"mounjaro-vs-ozempic","question":"Ozempic vs Mounjaro","answer":"Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes and weight loss, while Mounjaro (tirzepatide) is a newer GIP/GLP-1 receptor agonist showing superior weight loss results. Mounjaro targets two pathways compared to Ozempic's single pathway, making it potentially more effective for weight management.","answer_curated":true,"verdict":"Mounjaro demonstrates superior weight loss and diabetes control due to its dual-mechanism approach, making it the better choice for maximum results. However, Ozempic remains established with more clinical history, better availability, and lower cost, making it ideal for those seeking proven efficacy or budget-conscious patients. The choice depends on individual goals, insurance coverage, and medical history.","keyDifferences":[{"label":"Drug Class","winner":"b","entityAValue":"GLP-1 receptor agonist","entityBValue":"GIP/GLP-1 receptor agonist (dual agonist)"},{"label":"Average Weight Loss","winner":"b","entityAValue":"15-18% body weight","entityBValue":"20-22% body weight"},{"label":"FDA Approval for Weight Loss","winner":"a","entityAValue":"Approved (Wegovy brand, 2021)","entityBValue":"Approved (Zepbound brand, 2023)"},{"label":"Injection Frequency","winner":"tie","entityAValue":"Once weekly","entityBValue":"Once weekly"},{"label":"Available Dose Strengths","winner":"b","entityAValue":"0.5, 1.0, 2.4 mg","entityBValue":"2.5, 5, 7.5, 10, 12.5, 15 mg"}],"winner":{"slug":"mounjaro","name":"Mounjaro"},"confidence":"high","entities":[{"name":"Ozempic","slug":"ozempic","url":"https://www.aversusb.net/entity/ozempic","alternativesUrl":"https://www.aversusb.net/api/v1/alternatives/ozempic"},{"name":"Mounjaro","slug":"mounjaro","url":"https://www.aversusb.net/entity/mounjaro","alternativesUrl":"https://www.aversusb.net/api/v1/alternatives/mounjaro"}],"faqs":[{"question":"Which medication causes more side effects?","answer":"Both have similar side effect profiles including nausea, vomiting, and diarrhea, especially at higher doses. Mounjaro users report slightly more GI side effects initially due to its dual mechanism, but these typically resolve within 2-4 weeks. Ozempic has more long-term safety data due to its earlier release. Serious side effects like pancreatitis are rare with both medications."},{"question":"Can I switch from Ozempic to Mounjaro?","answer":"Yes, many patients successfully transition from Ozempic to Mounjaro under medical supervision. The switch typically involves stopping Ozempic and starting Mounjaro at a lower dose, titrating upward gradually. This transition often produces better weight loss results. Always consult your physician before switching medications."},{"question":"How long do I need to take these medications?","answer":"These are typically long-term medications. Studies show that weight loss is regained within 12 months of stopping treatment. For diabetes management, many patients require ongoing therapy. Your doctor will determine the appropriate duration based on your health goals and response to treatment."}],"attribution":{"source":"A Versus B","url":"https://www.aversusb.net/compare/mounjaro-vs-ozempic","license":"CC BY 4.0","citationFormat":"According to A Versus B (https://www.aversusb.net/compare/mounjaro-vs-ozempic), Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes and weight loss, while Mounjaro (tirzepatide) is a newer GIP/GLP-1 receptor agonist showing superior weight loss results.","dateModified":"2026-05-23T10:21:05.064Z"},"relatedQuestionsUrl":"https://www.aversusb.net/api/faq/mounjaro-vs-ozempic","relatedComparisonsUrl":"https://www.aversusb.net/api/v1/related/mounjaro-vs-ozempic","knowledgeGraphUrl":"https://www.aversusb.net/api/knowledge-graph/mounjaro-vs-ozempic","claimReviewSchema":{"@context":"https://schema.org","@type":"ClaimReview","@id":"https://www.aversusb.net/compare/mounjaro-vs-ozempic#claimreview","url":"https://www.aversusb.net/compare/mounjaro-vs-ozempic","inLanguage":"en-US","isAccessibleForFree":true,"conditionsOfAccess":"Free","claimReviewed":"Ozempic vs Mounjaro","reviewBody":"Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes and weight loss, while Mounjaro (tirzepatide) is a newer GIP/GLP-1 receptor agonist showing superior weight loss results. Mounjaro targets two pathways compared to Ozempic's single pathway, making it potentially more effective for weight management.","datePublished":"2026-05-23T10:21:05.063Z","dateModified":"2026-05-23T10:21:05.064Z","reviewRating":{"@type":"Rating","ratingValue":5,"worstRating":1,"bestRating":5,"alternateName":"High Confidence"},"author":{"@type":"Organization","@id":"https://www.aversusb.net/#organization","name":"A Versus B","url":"https://www.aversusb.net"},"itemReviewed":{"@type":"WebPage","@id":"https://www.aversusb.net/compare/mounjaro-vs-ozempic","url":"https://www.aversusb.net/compare/mounjaro-vs-ozempic","name":"Ozempic vs Mounjaro","inLanguage":"en-US"}}}